U.S. Stock Market Midday Update: AlphaTON Capital's acquisition plan for Forbes raises financial concerns, stock price plummets 17.88%

U.S. Stock Market Midday Update AlphaTON Capital fell 17.88%. Based on recent key news: On November 24, AlphaTON Capital submitted a strategic offer to acquire 51% of Forbes Media Holdings. This move raised concerns in the market about the company's financial condition, leading to a significant drop in stock price by 17.88%. Source: Reuters. The market reacted cautiously to the acquisition plan, with noticeable capital outflows. Stocks with High Trading Volume in the Industry Precision Science rose 44.97% over five days. Based on recent key news: On November 24, Jefferies downgraded Precision Science's rating from "Buy" to "Hold," but raised the target price from $90 to $105. Jefferies believes that as Abbott Laboratories acquires Precision Science for $23 billion, the stock price will approach the transaction price, providing shareholders with a fair acquisition premium. This news caused stock price fluctuations. On November 24, Craig-Hallum's William Bonello downgraded Precision Science's rating to "Hold," with a target price of $105. Nevertheless, Citi upgraded its rating to "Buy" on November 21, indicating differing views among analysts on the stock. On November 24, FactSet data showed that the median target price for Precision Science was raised from $97.5 to $105, with the stock price increasing by 7.69% over the past five days, outperforming the S&P index. The healthcare industry is experiencing active mergers and acquisitions, leading to increased market volatility. AbbVie rose 1.13%. Based on recent news: On November 24, AbbVie announced its participation in the 37th Annual Healthcare Conference hosted by Piper Sandler. The company's management will hold a fireside chat on December 3, which has attracted investor interest and driven the stock price up. On November 25, AbbVie and adMare BioInnovations jointly announced the launch of the AbbVie Biotechnology Innovators Award, aimed at promoting innovation and growth in Quebec's life sciences sector. This move has enhanced market confidence in the company's future development, resulting in a rise in stock price. On November 24, market analysts maintained AbbVie's rating at "Moderate Buy," but it was not included in the top recommended stocks list. Nevertheless, investors remain optimistic about its future performance, driving the stock price up. The healthcare sector has performed strongly recently, with noticeable capital inflows. Regeneron Pharmaceuticals rose 1.67%. Based on recent key news: On November 25, HSBC initiated coverage of Regeneron Pharmaceuticals with a "Buy" rating and a target price of $890. Analysts pointed out that the sales growth potential of Eylea HD and positive catalysts for cancer therapies are the main factors. This rating has boosted market confidence in Regeneron, driving the stock price up On November 24th, Scotiabank raised the target price for Regeneron Pharmaceuticals from $650 to $770. This increase reflects the market's optimistic expectations for the company's future growth, further supporting the upward trend in its stock price. On November 25th, the European Commission approved Dupixent for the treatment of moderate to severe chronic spontaneous urticaria patients. This approval expands the market application of Dupixent and enhances investors' expectations for the company's future revenue growth. The biotechnology sector has been active recently, with significant capital inflows. Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen rose 0.79%, with increased trading volume. Based on recent key news: On November 24th, Amgen executive Nancy A. Grygiel sold 3,139 shares of the company stock for a transaction amount of $1,058,667. This insider trading may raise market concerns about internal confidence in the company, leading to stock price fluctuations. On November 24th, Amgen announced its participation in the Evercore ISI HealthCONx conference on December 3rd. Company executives will speak at the event, which may enhance market attention on the company's future strategy and drive the stock price up. Recently, Amgen, as part of the NASDAQ 100 Index, has benefited from the overall positive market performance, with a market capitalization reaching $181.4 billion. The overall positive market performance has driven the stock price up